



# SHIFT. predicting biomarker distribution in medical images through speedy histopathological-to-immunofluorescent translation

Erik A. Burlingame<sup>1</sup>, M.S., Geoffrey F. Schau<sup>1</sup>, M.S., Christopher L. Corless<sup>3</sup>, M.D., Ph.D., Joe W. Gray<sup>2,3</sup>, Ph.D, Young Hwan Chang<sup>1</sup>, Ph.D.  
<sup>1</sup>{Computational Biology Program, <sup>2</sup>{Department of Biomedical Engineering, OHSU}}  
<sup>3</sup>Knight Cancer Institute, OHSU


For pathologists in the diagnostic lab or the rural clinic, when time or resources are scarce, **SHIFT** enables **accurate** and **near real-time** biomarker prediction from images of hematoxylin and eosin-stained (H&E) tissue at a **fraction of the cost** of traditional immunofluorescence (IF).

## Unmet Need


- Cancer incidence ↑, pathologist workforce ↓
- Multiplex imaging costs **time** and **\$\$\$**
- **Deep learning** can help save **time**, **\$\$\$** and **democratize** access to multiplex imaging

## Research Overview




- Powered by state-of-the-art **deep learning** models, **SHIFT** predicts biomarker distribution based on low-cost and highly-standardized H&E imaging.



## Technical overview of SHIFT modeling




## Key Results & Applications



## Commercial Potential

- ~**17,000** diagnostic labs in the US today
- Market from Mayo Clinic's Immunostains Lab **alone** estimated at **\$30 million/year**

### Global immunostains market (billions \$)



- **SHIFT** is novel, patentable, and enabled
- Provisional application filed at end of 2018

Art	Biomarker prediction	Histopathological validation
<i>in silico</i> labeling (Google)	✓	✗
TissueMark (Philips)	✗	✓
<b>SHIFT</b> (ours)	✓	✓

## Ongoing R&D

